Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30477009.
- Also identified by DOI 10.1001/jamaoncol.2018.5457 and PMC identifier 6440717.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Dexamethasone
- Lenalidomide
- Multiple Myeloma
- Oligopeptides